Conference abstractPublished 15 Mar 2019
Newer oral contraceptives protect against ovarian cancer in young women
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Aim: To assess the influence of contemporary hormonal contraceptives including progestogen-only products on overall and specific ovarian cancer risk. Design: Nationwide cohort study. Setting: Denmark Material: Women 15-49 years during the period 1995-2014 were eligible. They were excluded if they immigrated after 1995, had previous cancer, venous thrombosis or were treated for infertility before entry. Final study population included 1,879,227 women. Method: Relative Risk (RR) of ovarian cancer among users of any contemporary hormonal contraceptives was calculated using Poisson regression. Result: During 21.4 million person years, 1249 incident ovarian cancers occurred. Among ever users of hormonal contraception, 478 ovarian cancers were recorded over 13, 344, 531 person years. Never users had 771 ovarian cancers during 8, 150, 250 person years. Compared with never users, reduced risks of ovarian cancer occurred with current or recent use and former use of any hormonal contraception (relative risk 0.58 (95% confidence interval 0.49 to 0.68) and 0.77 (0.66 to 0.91), respectively). Relative risks among current or recent users decreased with increasing duration (from 0.82 (0.59 to 1.12) with ≤1 year use to 0.26 (0.16 to 0.43) with >10 years’ use; P<0.001 for trend). Similar results were achieved among women followed up to their first switch in contraceptive type. Little evidence of major differences in risk estimates by tumour type or progestogen content of combined oral contraceptives was seen. Use of progestogen-only products were not associated with ovarian cancer risk. Among ever users of hormonal contraception, the reduction in the age standardised absolute rate of ovarian cancer was 3.2 per 100 000 person years. Based on the relative risk for the never use versus ever use categories of hormonal contraception (0.66), the population prevented fraction was estimated to be 21%—that is, use of hormonal contraception prevented 21% of ovarian cancers in the study population. Conclusion: Contemporary combined hormonal contraceptives reduce ovarian cancer risk in young women, an effect related to duration of use and which diminishes after stopping. Our data suggests no protective effect from progestogen-only products.
Keywords
Subjects
HaematologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Blood Disorders and Treatment
- SubjectHaematology
- BylineArticles whose byline prints “Ojvind Lidegaard”
- BylineArticles whose byline prints “Iversen L”
- BylineArticles whose byline prints “Fielding S”
- BylineArticles whose byline prints “Morch L S”
- BylineArticles whose byline prints “Skovlund C W”
- BylineArticles whose byline prints “Hannaford P C”
